Drug Trial Radar · NCT04014023
Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
196
Planned (sponsor's estimate)
Start
Jul 10, 2019
Primary completion
Mar 2020
Study completion Jun 2020
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
DWP16001Drug
DWP16001 tablets
PlaceboDrug
DWP16001 placebo-matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HbA1cTime frame: at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Daewoong pharmatceutical
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.